Collateral and Berlex Announce Positive Results From Angina Gene Therapy Clinical Trial
Collateral Therapeutics (Nasdaq: CLTX) and Berlex Laboratories, the U.S. affiliate of Schering AG, Germany (NYSE: SHR) today announced that results of a […]
World's Largest Resource for Cardiovascular Perfusion
Collateral Therapeutics (Nasdaq: CLTX) and Berlex Laboratories, the U.S. affiliate of Schering AG, Germany (NYSE: SHR) today announced that results of a […]
Preoperative intravenous TXA reduced perioperative blood loss and transfusion requirements in a variety of surgical disciplines without increasing the risk of thromboembolic events. Therefore, it should be considered for prophylactic use in surgery to reduce operative bleeding.
This report introduces how such decision was made based on what supporting evidence and the diagnostic process leading to the initiation of surgical intervention. This report may help with decision-making process when confronted by blunt cardiac injury patients who need cardiac exploration.